Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX140-B in Type 2 Diabetes
NCT01028963Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2010
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of ilacirnon in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Amgen. Primary endpoint: Subject incidence of adverse events at 28 days. Started Jan 2010; status: completed.
02
Drugs
ilacirnon
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01028963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01028963.